KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ionis Pharmaceuticals (IONS) over the last 12 years, with Q3 2025 value amounting to $2.3 million.

  • Ionis Pharmaceuticals' Other Operating Expenses rose 11830.07% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 1276.92%. This contributed to the annual value of -$12000.0 for FY2024, which is 9254.66% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Other Operating Expenses is $2.3 million, which was up 11830.07% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Other Operating Expenses ranged from a high of $4.7 million in Q2 2022 and a low of $1.1 million during Q3 2024
  • For the 5-year period, Ionis Pharmaceuticals' Other Operating Expenses averaged around $2.8 million, with its median value being $2.6 million (2021).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 6779.38% in 2023, then soared by 11830.07% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Operating Expenses (Quarter) stood at $2.2 million in 2021, then skyrocketed by 65.48% to $3.7 million in 2022, then fell by 16.98% to $3.1 million in 2023, then increased by 25.09% to $3.8 million in 2024, then plummeted by 38.94% to $2.3 million in 2025.
  • Its Other Operating Expenses stands at $2.3 million for Q3 2025, versus $4.2 million for Q2 2025 and $1.5 million for Q1 2025.